4.3 Article

Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue

Journal

JOURNAL OF PSYCHOPHARMACOLOGY
Volume 26, Issue 5, Pages 744-750

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881111421969

Keywords

Placebo; active drug; randomized controlled trial; model; depression

Funding

  1. Pfizer Foundation
  2. AstraZeneca
  3. Bristol-Myers Squibb
  4. Eisai
  5. Eli Lilly
  6. GlaxoSmithKline
  7. Janssen Cilag
  8. Lundbeck
  9. Merck
  10. Novartis
  11. Organon
  12. Pfizer
  13. Sanofi-Aventis
  14. Schering-Plough
  15. Schwabe
  16. Sepracor
  17. Servier
  18. Wyeth

Ask authors/readers for more resources

In a recent paper, Horder and colleagues (Horder et al., 2010, J Psychopharmacol 25: 1277-1288) have suggested that the mainproblem in the Kirsch analysis is methodological. We argue that the results are similar irrespective of the method used. In our opinion the data suggest that placebo and drug effects are non-additive: antidepressants act independently of depression severity, while the placebo effect is present only in milder cases. While the response in the placebo group is due to unstable 'noise' and 'artefacts', the medication effect is reliable, valid and stable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available